Company Overview and News

0
DBV Technologies : Bilan semestriel du contrat de liquidité DBV Technologies et transfert du contrat à Oddo BHF

2018-07-13 globenewswire
DBV Technologies (Euronext : DBV - ISIN : FR0010417345 - Nasdaq : DBVT), laboratoire biopharmaceutique français, publie aujourd'hui le bilan semestriel de son contrat de liquidité avec Natixis. Par ailleurs, suite au partenariat devenu effectif entre Natixis et Oddo BHF, le contrat de liquidité portant sur ses actions confiées initialement à la société Natixis a été transféré en date d'effet du 02 juillet 2018 à la société Oddo BHF.
DBV

0
DBV Technologies: Half-Year Report on the DBV Technologies Liquidity Contract and Transfer to Oddo BHF

2018-07-13 globenewswire
DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today issued the Half-Year Report on its liquidity contract with Natixis. Due to the partnership between Natixis and Oddo BHF, the liquidity contract on DBV Technologies shares originally entrusted to Natixis, was transferred to Oddo BHF as of July 2, 2018.
DBV

0
DBV Technologies : Information mensuelle relative au nombre total des droits de vote et d'actions composant le capital social

2018-06-26 globenewswire
Information mensuelle relative au nombre total des droits de vote et d'actions composant le capital social
DBV

0
DBV Technologies : Monthly information regarding the total number of voting rights and total number of shares of the Company ...

2018-06-26 globenewswire
Monthly information regarding the total number of voting rights and total number of shares of the Company
DBV

0
DBV Technologies annonce les résultats de son Assemblée générale ordinaire et extraordinaire 2018 et la nomination de Joan Schmidt au poste d'Executive Vice President, Secrétaire Générale

2018-06-22 globenewswire
DBV Technologies annonce les résultats de son Assemblée générale ordinaire et extraordinaire 2018 et la nomination de Joan Schmidt au poste d'Executive Vice President, Secrétaire Générale
DBV

0
DBV Technologies Announces Results of its 2018 Ordinary and Extraordinary General Meeting and the Appointment of Joan Schmidt as Executive Vice President, General Counsel

2018-06-22 globenewswire
DBV Technologies Announces Results of its 2018 Ordinary and Extraordinary General Meeting and the Appointment of Joan Schmidt as Executive Vice President, General Counsel
DBV

163
Institutional Top Ideas: Great Point Partners

2018-06-19 seekingalpha
Great Point Partners has high returns of late and a significantly concentrated portfolio while avoiding extreme overweighting we´ve seen with certain other funds.
SGEN DBV IDRAW IDRA MRTX CASC

5
Aimmune Therapeutics: Special Situation Biotech Opportunity

2018-06-08 seekingalpha
Aimmune is the front-runner in the race to produce a medical therapy to prevent / control peanut allergies - its closest competitor, DBV Technologies has struggled of late.
DBV AIMT

0
DBV Technologies to Attend Upcoming Investor Conferences

2018-06-05 globenewswire
DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that members of its management team will present and host investor meetings at the following investor conferences in June 2018:
DBV

0
DBV Technologies invitée à présenter lors des prochaines Conférences Investisseurs

2018-06-05 globenewswire
DBV Technologies (Euronext : DBV - ISIN : FR0010417345 - Nasdaq : DBVT), société biopharmaceutique française, annonce aujourd'hui que des membres de son management ont été invités à présenter ainsi qu'à tenir des rendez-vous investisseurs en juin 2018 lors des conférences investisseurs suivantes:
DBV

0
DBV Technologies : Correctif - Assemblée Générale Mixte du 22 juin 2018 - Modalités de mise à disposition des documents préparatoires à l'Assemblée

2018-06-04 globenewswire
DBV Technologies (Euronext : DBV - ISIN : FR0010417345 - NASDAQ : DBVT), société biopharmaceutique française, annonce aujourd'hui la tenue de son Assemblée Générale Mixte le mercredi 22 juin 2018 à 08h30 (heure de Paris) au siège de la société 177-181 Avenue Pierre Brossolette à Montrouge (92120).
DBV

0
DBV Technologies : Assemblée Générale Mixte du 22 juin 2018 - Modalités de mise à disposition des documents préparatoires à l'Assemblée

2018-06-01 globenewswire
DBV Technologies (Euronext : DBV - ISIN : FR0010417345 - NASDAQ : DBVT), société biopharmaceutique française, annonce aujourd'hui la tenue de son Assemblée Générale Mixte le mercredi 22 juin 2018 à 08h30 (heure de Paris) au siège de la société 177-181 Avenue Pierre Brossolette à Montrouge (92120).
DBV

0
DBV Technologies: Ordinary and Extraordinary General Meeting of June 22, 2018 - Procedures for Obtaining Preparatory Documents for the General Meeting

2018-06-01 globenewswire
DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - NASDAQ: DBVT) announced today that it will hold its Ordinary and Extraordinary General Meeting on June 22, 2018 at 8:30 a.m. CEST at the Company's headquarters located at 177-181 Avenue Pierre Brossolette - 92120 Montrouge, France.
DBV DBVT

0
DBV Technologies : Information relative au nombre total des droits de vote et d'actions composant le capital social en date du 18 mai 2018

2018-05-29 globenewswire
Information mensuelle relative au nombre total des droits de vote et d'actions composant le capital social
DBV

0
DBV Technologies : Information regarding the total number of voting rights and total number of shares of the Company on May 18th, 2018

2018-05-29 globenewswire
Monthly information regarding the total number of voting rights and total number of shares of the Company
DBV

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...